Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks Transcript

Core Insights - The company, Halozyme, is a pioneer in the use of hyaluronidases for large volume subcutaneous delivery, which has led to the development of its core platform, ENHANZE, licensed to major pharmaceutical companies for transforming IV drugs to subcutaneous administration [1] Group 1 - The company has achieved 10 approvals to date, indicating significant progress in its product offerings [2]